This sensitized for treatment with the JAK1/JAK2 inhibitor ruxolitinib, which is approved for the treatment of myeloproliferative neoplasms and was shown to penetrate the blood–brain barrier in mice [28, 68]. Here, JAK2 is linked to myeloproliferative disorder.